Lakeshore Acquisition I Corp

Prosomnus, Inc. is a medical technology company. It engages in the development, manufacture and marketing of precision intraoral medical devices. The company is headquartered in Wilmington, DE.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prosomnus, Inc. is a medical technology company, which engages in the business of developing, manufacturing, and marketing precision intraoral medical devices. It focuses on treating and managing patients with obstructive sleep apnea. The company was founded by Leonard Liptak and Sung Kim in 2006 and is headquartered in Pleasanton, CA.

SAN FRANCISCO , Dec. 2, 2022 /PRNewswire/ -- Lakeshore Acquisition I Corp. (Nasdaq: LAAA) ("Lakeshore") today announced that its shareholders have approved all proposals related to the previously announced business combination (the "Business Combination") with ProSomnus Holdings, Inc. ("ProSomnus") at a special meeting of shareholders held on December 2, 2022. Approximately 92.4% of the votes cast at the meeting on the Business Combination proposal, representing approximately 80.5% of Lakeshore's outstanding shares, voted to approve the Business Combination.

Lakeshore Acquisition Corp I Shareholders Approve Business Combination with ProSomnus

Generated record quarterly revenues, and expects merger with Lakeshore Acquisition I Corp. to close in the fourth quarter of 2022

ProSomnus Reports Third Quarter Financial Results and Provides Corporate Update

32,219-square-foot facility will quintuple growth and create local jobs

ProSomnus® to Open New Global Headquarters and Manufacturing Center of Excellence, Increasing Manufacturing Capacity and Efficiency

SAN FRANCISCO , June 3, 2022 /PRNewswire/ -- ProSomnus, a leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the results of three studies evaluating its FDA-cleared Oral Appliance Therapy (OAT) devices in the treatment of OSA. ProSomnus will share data in three poster presentations at SLEEP 2022, the Annual Meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held from June 4-8 in Charlotte, North Carolina.

ProSomnus® to Present Data at SLEEP 2022, the Annual Meeting of the American Academy of Sleep Medicine and the Sleep Research Society

ProSomnus is a pioneer of precision intraoral devices, a new option for treating mild to moderate obstructive sleep apnea (OSA) A number of scientific studies indicate ProSomnus precision intraoral devices as the most effective treatment for mild and moderate obstructive sleep apnea Obstructive sleep apnea is a chronic medical disease linked with significant comorbidities that affects approximately one billion people worldwide and 74 million Americans, approximately 80 percent of whom are undiagnosed ProSomnus precision oral devices are mass customized and manufactured based upon each patient's anatomy and treatment plan, enabling greater patient comfort, ease of use and dose control ProSomnus's oral appliance therapy devices have been prescribed to over 150,000 patients and are considered more comfortable and less invasive than continuous positive airway pressure (CPAP) therapy The implied initial enterprise value of the business combination is approximately $168 million The transaction is expected to be supported by a $30 million PIPE of senior and junior convertible notes led and backstopped by Cohanzick Management, LLC and CrossingBridge Advisors, LLC The business combination is expected to be completed in the third quarter of 2022, and the combined company is expected to be listed on the Nasdaq Capital Market under the symbol "OSA" This transaction is expected to accelerate ProSomnus's development and commercialization of its oral appliance therapy devices SAN FRANCISCO, May 10, 2022 /PRNewswire/ -- ProSomnus Holdings Inc. ("ProSomnus"), the leader in patient-preferred medical devices for the treatment of obstructive sleep apnea, and Lakeshore Acquisition I Corp. ("Lakeshore") (Nasdaq: LAAA) today announced that they have entered into a definitive business combination agreement. Upon closing, the combined company is expected to change its name to ProSomnus, Inc. and its Class A common stock is expected to be traded on the Nasdaq Capital Market under the symbol "OSA.

ProSomnus®, Leader in Patient-Preferred Sleep Apnea Therapy, to be Listed on Nasdaq Through Business Combination with Lakeshore Acquisition I Corp.

News for Lakeshore Acquisition I Corp Stock (LAAA)